CN113264975A

CN113264975A - Extract with anti-inflammatory activity extracted from Rosa roxburghii rhizome and application thereof

Info

Publication number: CN113264975A
Application number: CN202110383461.1A
Authority: CN
Inventors: 杨小生; 李良群; 王瑜; 李齐激; 梁勇; 王丽; 罗忠圣; 李立郎; 杨娟
Original assignee: Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Current assignee: Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority date: 2021-04-09
Filing date: 2021-04-09
Publication date: 2021-08-17
Anticipated expiration: 2041-04-09
Also published as: CN113264975B

Abstract

The invention discloses an extract with anti-inflammatory activity extracted from roxburgh rose rhizome and application thereof, wherein the extract comprises compounds 1,2, 3, 4, 5, 6 and 7, and the preparation method comprises the steps of cleaning and cutting fresh roxburgh rose rhizome, extracting by refluxing with 80% ethanol, and concentrating the extracting solution to obtain an extract. Using chloroform: eluting with methanol at a ratio of 30:1,20:1 and 10:1 to obtain compounds 1,2 and 3; using chloroform: methanol 8:1 elution afforded compound 5; and then purified by Sephdex-LH-20 gel to obtain compounds 4, 6 and 7. The compounds 4, 6 and 7 disclosed by the invention are separated from the roxburgh rose root for the first time; the seven compounds have good anti-inflammatory activity for screening the anti-inflammatory activity of RAW264.7 in vitro cells.

Description

Extract with anti-inflammatory activity extracted from Rosa roxburghii rhizome and application thereof

Technical Field

The invention belongs to the field of natural medicines, and particularly relates to an extract with anti-inflammatory activity extracted from roxburgh rose rhizomes and application thereof.

Background

Rosa roxburghii Tratt is the fruit of filature flower of Rosa plants in Rosaceae, and is named as Ananas comosus, Shixiao fruit and the like (Nanying et al, 2015), and is mainly distributed in southwest areas in China, wherein the Rosa roxburghii Tratt is most distributed in Guizhou. Rosa roxburghii has high medicinal value, the root, stem, leaf, flower and fruit of Rosa roxburghii can be used as medicines (Songwei Wan, Liu Qing hong, 2012), the nature and taste are sour and astringent, the Rosa roxburghii has the effects of invigorating spleen to promote digestion, astringing to arrest diarrhea, and the Rosa roxburghii is mainly used for treating diseases such as food retention and abdominal distension, diarrhea and dysentery (Guizhou province drug administration, 2003). Wherein the Rosa roxburghii rhizome decoction has effects of treating acute bacillary dysentery and chronic gastric ulcer (Chenyunzhi, Liu' an Ying, 2007; Chen Jian Hua, 2001). The Roxburgh rose rhizome decoction is commonly used by people in Yao nationality of Guizhou litchi area for treating digestive system diseases and leukorrheal diseases, has good treatment effect on dysentery and diarrhea of various animals such as pigs, cattle, sheep and the like (Anxiao et al, 2015; Yusheng et al, 2016; Rogoche, Baicai, 2008; Von hong Qian, 1984), has good treatment effect on the diseases, can cause inflammation in the processes of generation and development of the diseases, and carries out anti-inflammatory activity screening on the separated compounds for further clarifying the basis of the anti-inflammatory active substance of the Roxburgh rose rhizome.

Disclosure of Invention

The invention aims to provide an extract with anti-inflammatory activity extracted from roxburgh rose rhizomes, a preparation method thereof and application of the extract in preparing anti-inflammatory drugs.

The purpose of the invention and the main technical problem of solving the invention are realized by adopting the following technical scheme: an extract having anti-inflammatory activity extracted from the rhizomes of Rosa roxburghii Tratt, said extract comprising: rosa roxburghii glycoside (1), Rosa multiflora glycoside (2), Rosa acid (3), beta-D-glucopyranosyl- (2a → 1b) -2 a-O-beta-L-arabinopyranosyl- (2b → 1c) -2 b-O-beta-L-arabinopyranosyl- (2c → 1D) -2 c-O-beta-L-arabinopyranosyl-rano syl- (2D → 1e) -2D-O-beta-L-arabinopyranosyl-ranosyl- (2e → 1f) -2 e-O-beta-L-arabinopyranoside (4), catechin (5), 3-O-metallac acid 3' -O-beta-D-xylopyranoside (6), 3-O-metallac acid-4-O-alpha-L-rhodoside (7), the preparation method comprises cleaning fresh fructus Rosae Normalis, cutting into pieces, soaking in 80% ethanol, reflux-extracting with 80% ethanol for 3 times, filtering, mixing extractive solutions, concentrating under reduced pressure to remove ethanol smell, concentrating at 60 deg.C to obtain extract, separating with silica gel column chromatography, selecting chloroform: methanol 10:1, 5:1,1:1,0:1 as eluent to obtain four parts, wherein part a, part B, part C, part D; then, part C was extracted with chloroform: methanol-30: 1,20:1,10:1 to give compound 1 and compound 2; part B was extracted with chloroform: gradient elution with methanol 20:1,10:1, decompression concentration and recrystallization to obtain compound 3; part D was extracted with chloroform: methanol 8:1 elution afforded compound 5; and purifying other fractions by Sephadex-LH-20 gel chromatography column chromatography to obtain compound 4, compound 6 and compound 7.

The root and stem of the roxburgh rose are Guinong No. 5 roxburgh rose.

The

compounds

1,2, 3, 4, 5, 6 and 7 obtained by the steps have obvious inhibition effect on NO released by mouse macrophage RAW264.7 induced by LPS, and can be applied to anti-inflammatory drugs.

When said

compounds

1,2, 3, 4, 5, 6 and 7 are used as medicaments, they can be used directly or in the form of a pharmaceutical composition containing 0.1-99% of said compounds, the remainder being pharmaceutically acceptable carriers or excipients.

The pharmaceutically acceptable carrier or excipient is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical adjuvants.

The pharmaceutical composition is used in the form of a dosage per unit body weight.

The dosage form of the pharmaceutical composition comprises: injection, suspension, emulsion, solution, syrup, tablet, capsule, granule, spray, and aerosol.

Compared with the prior art, the invention has obvious advantages and beneficial effects. According to the technical scheme, the extract obtained from the roxburgh rose rhizome has an obvious inhibiting effect on NO released by mouse macrophage RAW264.7 induced by LPS, has a treatment effect on various diseases caused by inflammation, is developed into a medicament with anti-inflammatory activity, and has an important application prospect.

Drawings

Figure 1 is a structural formula for

compounds

1,2, 3, 4, 5, 6 and 7.

Figure 2 is a graph of the effect of

compounds

1,2, 3, 4, 5, 6 and 7 on mouse macrophage proliferation.

FIG. 3 shows the effect on NO expression in RAW264.7 cells.

Detailed Description

The following detailed description of the anti-inflammatory extract extracted from the rhizomes of rosa roxburghii tratt according to the present invention, and the specific embodiments, features and effects thereof will be described in detail with reference to the accompanying drawings and preferred embodiments.

An extract having anti-inflammatory activity extracted from the rhizomes of Rosa roxburghii Tratt, said extract comprising: rosa roxburghii glycoside (1), Rosa multiflora glycoside (2), Rosa acid (3), beta-D-glucopyranosyl- (2a → 1b) -2 a-O-beta-L-arabinopyranosyl- (2b → 1c) -2 b-O-beta-L-arabinopyranosyl- (2c → 1D) -2 c-O-beta-L-arabinopyranosyl-rano syl- (2D → 1e) -2D-O-beta-L-arabinopyranosyl-ranosyl- (2e → 1f) -2 e-O-beta-L-arabinopyranoside (4), catechin (5), 3-O-metallac acid 3' -O-beta-D-xylopyranoside (6), 3-O-metallac acid-4-O-alpha-L-rhodoside (7), the preparation method comprises cleaning fresh fructus Rosae Normalis, cutting, extracting with 80% ethanol under reflux for 3 times, filtering, mixing extractive solutions, concentrating under reduced pressure to remove ethanol smell, concentrating at 60 deg.C to obtain extract, separating with silica gel column chromatography, selecting chloroform: methanol is 10; 1,5:1,1:1,0:1 as eluent to obtain four parts, wherein, part A, part B, part C and part D; then, part C was extracted with chloroform: methanol-30: 1,20:1,10:1 to give compound 1 and compound 2; part B was extracted with chloroform: gradient elution with methanol 20:1,10:1, decompression concentration and recrystallization to obtain compound 3; part D was extracted with chloroform: methanol 8:1 elution afforded compound 5; and purifying other fractions by Sephadex-LH-20 gel chromatography column chromatography to obtain compound 4, compound 6 and compound 7.

The root and stem of the roxburgh rose are Guinong No. 5 roxburgh rose.

The

compounds

When said

compounds

Example 1

Cleaning fresh roxburgh rose rhizome (40kg), cutting, extracting with 80% ethanol under reflux for 3 times, each time for 2 hours, filtering, combining the extracts, concentrating under reduced pressure until no alcohol smell exists, transferring to a water bath kettle (60 ℃) to concentrate into extract to obtain 1.15kg of extract, performing primary separation on the sample by adopting silica gel column chromatography, selecting chloroform: methanol 10:1, 5:1,1:1,0:1 as eluent gave four fractions, of which 11g of a fraction, 97g of B fraction, 69g of C fraction, 263g of D fraction. Then, part C was extracted with chloroform: methanol 630:1,20:1,10:1:1 elution gave compound 1(65mg) and compound 2(42 mg); part B was extracted with chloroform: gradient elution with methanol 20:1,10:1, concentration under reduced pressure and recrystallization afforded compound 3(35 mg); part D was extracted with chloroform: methanol 8:1 elution afforded compound 5(40 mg); the other fractions were concentrated under reduced pressure and purified by Sephadex-LH-20 gel chromatography to give compound 4(200mg), compound 6(25mg) and compound 7(18 mg). .

The map data are as follows:

compound 1: white powder (methanol); ESI-MS M/z 673[ M + Na ]]⁺；¹H NMR(600MHz,MeOD)δ：5.35(1H，d，J＝12.0Hz，glc-1)，5.32(1H，br s，H-12)，2.52(1H，s，H-18)，2.65(1H，m，H-3)，1.35(3H，s，CH₃-27),1.20(3H，s，CH₃-29)，0.98(3H，d，CH₃-25)，0.97(3H，d，CH₃-23)，0.92(3H，d，J＝9.0Hz，CH₃-30)，0.84(3H，s，CH₃-23),0.75(3H，s，CH₃-24)；¹³C NMR(150MHz,MeOD)δ：42.5(C-1)，67.3(C-2)，80.1(C-3)，39.6(C-4)，49.2(C-5)，22.6(C-6)，34.2(C-7)，41.5(C-8)，48.5(C-9)，39.4(C-10)，24.5(C-11)，129.5(C-12)，139.5(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.2(C-18)，73.5(C-19)，43.0(C-20)，27.3(C-21)，38.5(C-22)，29.3(C-23)，16.6(C-24)，17.2(C-25)，19.3(C-26)，24.8(C-27)，178.5(C-28)，27.2(C-29)，17.7(C-30)，95.6(C-1′)，73.5(C-2′)，78.6(C-3′)，71.3(C-4′)，78.5(C-5′)，62.5(C-6′)。

Compound 2: white powder (methanol); ESI-MS M/z 673[ M + Na ]]⁺；¹H NMR(600MHz,MeOD)δ：5.35(1H，d，J＝12.0Hz，glc-1)，5.32(1H，br s，H-12)，2.50(1H，s，H-18)，1.32(3H，s，CH₃-27)，1.28(3H，s，CH₃-29)，1.15(3H，s，CH₃-25)，1.05(3H，s，CH₃-23)，0.92(3H，d，J＝7.5Hz，CH₃-30)，0.80(3H，s，CH₃-26),0.75(3H，s，CH₃-24)；¹³C NMR(150MHz,MeOD)δ：48.2(C-1)，69.5(C-2)，84.2(C-3)，39.2(C-4)，56.5(C-5)，19.7(C-6)，34.0(C-7)，41.5(C-8)，48.6(C-9)，40.6(C-10)，24.8(C-11)，129.5(C-12)，139.7(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.0(C-18)，73.5(C-19)，43.0(C-20)，27.3(C-21)，36.9(C-22)，29.3(C-23)，17.6(C-24)，16.5(C-25)，17.5(C-26)，24.9(C-27)，178.5(C-28)，28.6(C-29)，25.2(C-30)，95.8(C-1′)，73.6(C-2′)，78.2(C-3′)，71.3(C-4′)，78.5(C-5′)，62.3(C-6′)。。

Compound 3: white powder (methanol); ESI-MS M/z 511[ M + Na ]]⁺；¹H NMR(600MHz,MeOD)δ：5.30(1H，br s，H-12)，3.91(1H，br d，J＝18.0Hz，H-3)，3.31(1H，overlop，H-2)，2.50(1H，s，H-18)，1.35(3H，s，CH₃-27)，1.28(3H，s，CH₃-29)，1.1,8(3H，s，CH₃-25)，0.98(3H，s，CH₃-23)，0.92(3H，d，J＝10.5Hz，CH₃-30)，0.85(3H，s，CH₃-26),0.75(3H，s，CH₃-24)；¹³C NMR(150MHz,MeOD)δ：42.3(C-1)，67.2(C-2)，80.2(C-3)，41.2(C-4)，49.3(C-5)，24.5(C-6)，34.0(C-7)，39.3(C-8)，48.2(C-9)，39.5(C-10)，27.2(C-11)，129.3(C-12)，140.0(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.0(C-18)，73.5(C-19)，43.0(C-20)，19.2(C-21)，36.9(C-22)，39.0(C-23)，29.3(C-24)，17.5(C-25)，16.6(C-26)，27.0(C-27)，182.5(C-28)，24.9(C-29)，16.9(C-30)。

Compound 4: yellow semi-solid (methanol); ESI-MS M/z 840[ M-H ]]-；¹H NMR(600MHz,MeOD)δ：4.45(d，H-1a)，3.96(dd，H-2a)，3.48(m，H-3a)，3.83(m，H-4a)，3.95(m，H-5a)，3.15(d，H-6a)，5.08(d，H-1b)，4.03(dd，H-2b)，3.45(m，H-3b)，3.85(m，H-4b)，3.22(d，H-5b)，4.63(d，H-1c)，3.94(m，H-2c)，3.46(H-3c)，3.75(m，H-4c)，3.25(d，H-5c)，4.85(br s，H-1d)，4.05(dd，H-2d)，3.43(m，H-3d)，3.73(m，H-4d)，3.35(d，H-5d)，4.83(br s，H-1e)，4.05(dd，H-2e)，3.46(m，H-3e)，3.73(m，H-4e)，3.30(br s，H-5e)，4.50(d，H-1f)，3.92(dd，H-2f)，3.56(m，H-3f)，3.60(m，H-4f)，3.35(d，H-5f)；¹³C NMR(150MHz,MeOD)δ：99.5(C-1a)，84.2(C-2a)，69.8(C-3a)，69.5(C-4a)，76.5(C-5a)，60.5(C-6a)，94.2(C-1b)，83.1(C-2b)，76.3(C-3b)，66.0(C-4b)，62.5(C-5b)，91.3(C-1c)，83.1(C-2c)，74.6(C-3c)，64.9(C-4c)，62.6(C-5c)，98.5(C-1d)，78.4(C-2d)，73.8(C-3d)，65.0(C-4d)，62.6(C-5d)，103.5(C-1e)，78.1(C-2e)，73.1(C-3e)，72.0(C-4e)，64.5(C-5e)，105.5(C-1f)，77.3(C-2f)，71.2(C-3f)，63.8(C-4f)，63.5(C-5f)。

Compound 5: yellow powder (methanol); ESI-MS M/z 289[ M-H ]]^-；¹H NMR(600MHz,MeOD)δ：8.03(4H，s，OH×4)，4.55(1H，d，J＝10.5Hz，H-2)，5.95(1H，d，J＝2.25Hz，H-6)，6.01(1H，d，J＝2.25Hz，H-8)，6.91(1H，br s，H-2′)，6.75(1H，br d，J＝12Hz，H-5′)，6.81(1H，d，J＝12Hz，H-6′)，4.05(1H，br s，OH×3)；¹³C NMR(150MHz,MeOD)δ：82.5(C-2)，68.2(C-3)，28.5(C-4)，157.3(C-5)，95.6(C-6)，157.2(C-7)，95.2(C-8)，157.0(C-9)，99.8(C-10)，132.0(C-1′)，115.5(C-2′)，145.4(C-3′)，145.3(C-4′)，115.3(C-5′)，119.3(C-6′)。

Compound 6: yellow needles (dimethylsulfoxide); ESI-MS M/z 919[2M + Na ]]⁺；¹H NMR(600MHz,DMSO)δ：7.55(1H，s，H-5)，7.72(1H，s，H-5′)，3.95(3H，s，-OCH₃),5.00(1H，d，J＝14Hz，H-1")；¹³C NMR(150MHz,DMSO)δ：113.2(C-1)，141.5(C-2)，140.1(C-3)，152.4(C-4)，111.3(C-5)，111.3(C-6)，158.7(C-7)，114.1(C-1′)，141.7(C-2′)，135.5(C-3′)，146.5(C-4′)，107.3(C-5′)，111.4(C-6′)，158.5(C-7′)，60.9(C₃-OCH₃),102.5(C-1")，72.5(C-2")，75.3(C-3")，69.2(C-4")，65.1(C-5")。

Compound 7: yellow needles (dimethylsulfoxide); ESI-MS M/z 461[ M-H ]]^-；¹H NMR(600MHz,DMSO)δ：7.48(1H，s，H-5)，7.60(1H，s，H-5′)，3.95(3H，s，-OCH₃),5.42(1H，s，H-1")；¹³C NMR(150MHz,DMSO)δ：107.3(C-1)，140.1(C-2)，136.2(C-3)，146.5(C-4)，111.3(C-5)，111.5(C-6)，158.7(C-7)，114.1(C-1′)，141.7(C-2′)，141.6(C-3′)，152.6(C-4′)，111.6(C-5′)，113.0(C-6′)，158.5(C-7′)，60.9(C₃-OCH₃),100.3(C-1")，70.2(C-2")，70.5(C-3")，71.5(C-4")，69.8(C-5"),17.8(C-6")。

And (3) tablet preparation: 10mg of compound 2, 160mg of lactose, 60mg of starch and 20mg of magnesium stearate;

the preparation method comprises the following steps: mixing the extract, lactose and starch, moistening with water, sieving the moistened mixture, drying, sieving, adding magnesium stearate, and tabletting to obtain tablet with weight of 250mg and compound content of 10 mg.

Example 2

An ampoule agent: 2mg of Compound 1 obtained in example 1,10 mg of sodium chloride;

the preparation method comprises the following steps: the compound and sodium chloride are dissolved in an appropriate amount of water for injection, and the resulting solution is filtered and filled into an ampoule under aseptic conditions.

Example 3

And (3) capsule preparation: 10mg of compound 3 obtained in example 1, 187mg of lactose, 3mg of magnesium stearate;

the preparation method comprises the following steps: mixing compound 3 with adjuvants, sieving, mixing, and encapsulating the obtained mixture into hard gelatin capsules with each capsule weighing 200mg and active ingredient 10 mg.

In order to further analyze that the

compounds

1,2, 3, 4, 5, 6 and 7 have obvious inhibition effect on NO released by LPS-induced mouse macrophage RAW264.7, the obtained

compounds

1,2, 3, 4, 5, 6 and 7 are subjected to the following activity verification experiments:

1. the experimental method comprises the following steps:

(1) MTT method for detecting cell proliferation activity

The MTT method is adopted to detect the influence of each monomeric compound on the proliferation activity of mouse macrophage RAW264.7, and the safe and effective molar concentration is screened. Observing under an inverted microscope, taking cells in logarithmic growth phase, adjusting the cell concentration to be 2 multiplied by 104/ml, inoculating the cells into a 96-well plate, culturing 100 mu L of each well in an incubator with 37 ℃ and 5% CO2 for 24h until the cells adhere to the wall, adding liquid medicines with different molar concentrations as administration groups, setting the concentration to be 3.125, 6.25, 12.5, 25, 50, 100, 200, 400 and 800 mu mol.L-1, additionally arranging a blank control (only adding culture solution) and a negative control (containing cells and culture solution), adding 20 mu L of MTT (5mg/ml PBS solution) into each well, continuing culturing for 4h, after the culture is finished, sucking supernatant, adding 150 mu L of DMSO into each well, shaking for 10min in a dark place, and detecting the absorbance value at 570 nm.

(2) Griess method for detecting NO release amount of mouse mononuclear macrophage

Anti-inflammatory activity of each monomeric compound was evaluated using LPS-induced mouse macrophage RAW264.7 inflammatory model. Taking cells in logarithmic growth phase, washing twice by PBS, adding a proper amount of culture medium, uniformly blowing, counting cell plates, adding complete culture medium to dilute the cell concentration to 1 × 105/ml, inoculating the cell concentration to a 96-well plate, culturing for 24h, then adhering the cell to the wall, adding a sample to be detected which is diluted by the culture medium into each well, dividing the sample into dexamethasone (a positive control group), LPS (a negative control group), a blank group and an LPS + drug group, setting 3 multiple wells for each concentration, continuously culturing for 24h, taking a new 96-well plate, adding 50 μ l of culture medium supernatant into each well, and operating according to the instruction of an inflammatory factor kitThen, the amount of NO released was measured. Measuring absorbance value with enzyme labeling instrument at 540nm, calculating the inhibition rate IC of drug on release of mouse macrophage RAW264.7 inflammatory factor NO by GraphPad Prism 7 biological statistics software₅₀The value is obtained.

2. Test results

As can be seen from FIG. 2, when the concentrations of the monomers are less than or equal to 50. mu. mol/L, the cell proliferation activities of the

compounds

1,2, 3, 4, 5, 6 and 7 are all greater than 90% compared to the blank control, which indicates that the concentrations of the monomers are less than or equal to 50. mu. mol/L, the proliferation of the mouse macrophage RAW264.7 is hardly affected, and the concentration range can be considered as a safe concentration range.

As can be seen in FIG. 3, NO release after LPS stimulation was significantly higher than that of the control group (P)<0.001), indicating that molding was successful. Dexamethasone was used as a positive control in the assay (half inhibitory concentration IC)₅₀22.46 μ M), the compound can reduce the release amount of NO under the condition of molar concentration of 3.125, 6.25, 12.5, 25 and 50 μmol/L compared with the LPS group, and has dose dependence. From the above studies, it can be seen that compound 1, compound 2, compound 3, compound 4, compound 5, compound 6 and compound 7 showed better anti-inflammatory activity, IC of each compound, compared to the positive drug dexamethasone₅₀The values are shown in Table 1.

TABLE 1 respective Compounds IC₅₀Value summary table

The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are within the scope of the present invention without departing from the technical spirit of the present invention.

Claims

1. An extract having anti-inflammatory activity extracted from the roots and stems of Rosa roxburghii Tratt, characterized in that: the extraction comprises the following steps: rosa roxburghii glycoside (1), multiflora rose glycoside (2), rosanic acid (3), oligo se (4), catechin (5), 3-O-methyl lactic acid 3' -O-beta-D-xylopyranoside (6), 3-O-methyl lactic acid-4-O-alpha-L-rham-nonpyranoside (7) compounds, the structural formula of which are respectively as follows:

the preparation method comprises cleaning fresh fructus Rosae Normalis, cutting into pieces, extracting with 80% ethanol under reflux for 3 times, filtering, mixing extractive solutions, concentrating under reduced pressure to remove ethanol smell, concentrating at 60 deg.C to obtain extract, separating by silica gel column chromatography, selecting chloroform: methanol 10:1,5:1,1:1,0: 1 as eluent to obtain four parts, wherein, part A, part B, part C and part D; then, part C was extracted with chloroform: methanol 630:1,20:1,10:1:1 elution gave compound 1 and compound 2; part B was extracted with chloroform: gradient elution with methanol 20:1,10:1, decompression concentration and recrystallization to obtain compound 3; part D was extracted with chloroform: methanol 8:1 elution afforded compound 5; and concentrating other obtained fractions under reduced pressure, and purifying by Sephadex-LH-20 gel chromatography column chromatography to obtain compound 4, compound 6 and compound 7.

2. The extract with anti-inflammatory activity extracted from the rhizomes of rosa roxburghii tratt according to claim 1, wherein: the root and stem of the roxburgh rose are Guinong No. 5 roxburgh rose.

3. The use of an extract of Rosa roxburghii rhizomes with anti-inflammatory activity as claimed in claim 1, wherein: the compounds 1,2, 3, 4, 5, 6 and 7 have obvious inhibition effect on NO released by mouse macrophage RAW264.7 induced by LPS, and can be applied to anti-inflammatory drugs or veterinary drugs.

4. The use of an extract of Rosa roxburghii rhizomes with anti-inflammatory activity as claimed in claim 3, wherein: when said compounds 1,2, 3, 4, 5, 6 and 7 are used as medicaments, they can be used directly or in the form of a pharmaceutical composition containing 0.1-99% of said compounds, the remainder being pharmaceutically acceptable carriers or excipients.

5. The use of an extract of Rosa roxburghii rhizomes with anti-inflammatory activity as claimed in claim 4, wherein: the pharmaceutically acceptable carrier or excipient is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical adjuvants.

6. The use of an extract of Rosa roxburghii rhizomes with anti-inflammatory activity as claimed in claim 4, wherein: the pharmaceutical composition is used in the form of a dosage per unit body weight.

7. The use of an extract of Rosa roxburghii rhizomes with anti-inflammatory activity as claimed in claim 4, wherein: the dosage form of the pharmaceutical composition comprises: injection, suspension, emulsion, solution, syrup, tablet, capsule, granule, spray, and aerosol.